Audentes Therapeutics

Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients with severe, life-threatening rare diseases. We are currently conducting Phase 1/2 clinical studies on our lead product candidates: AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM) and AT342 for the treatment of Crigler-Najjar Syndrome. We also have two additional product candidates in development, including AT845 for Pompe disease and AT307 for Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT) caused by the CASQ2 subtype. We are a dedicated, experienced, and passionate team committed to building strong global relationships with patients, researchers, and the medical community.